Phosphate Phebra effervescent tablets should be dissolved in ⅓ to ½ glass of water and taken orally.

The dosage should be adjusted to suit the requirements of individual patients.

ADULTS:

Hypercalcaemia: up to 6 tablets daily (adjustment being made according to requirements).

Vitamin D-resistant rickets: 4-6 tablets daily.

CHILDREN:

Hypercalcaemia: up to 3 tablets daily (adjustment being made according to requirements).

Vitamin D-resistant rickets: 2-3 tablets daily.

Store below 25°C. The tablets must be stored in the tightly closed original container.

Keep out of reach of children.

Always read the label and follow the directions for use.

Consideration should be given to the sodium and potassium content of Phosphate Phebra tablets (see DESCRIPTION) before administration to patients suffering from conditions associated with significant electrolyte imbalance, or impaired renal function.

In cases where restricted sodium intake is indicated, e.g., in the treatment of congestive cardiac failure, hypertension, preeclamptic toxaemia, etc., the sodium and potassium content of Phosphate Phebra tablets should be taken into consideration.

Soft tissue calcification and nephrocalcinosis have been reported in isolated cases following intravenous therapy with phosphate. This is thought to be a function of dosage and rapidity of phosphate administration. While such effects appear less likely to occur following treatment with oral phosphates, careful surveillance of patients is recommended.

Concurrent administrations of Phosphate Phebra tablets with antacids, containing agents such as aluminium hydroxide, calcium, or magnesium salts, may result in the displacement of calcium from binding to oral phosphate, thus reducing the efficacy of this medication.

This medicine may not be right for you. Read the warnings before purchase.

Keep out of reach of children.

Supplements may only be of assistance if dietary intake is inadequate. Vitamin and mineral supplements are not a replacement for a healthy diet.